AU2020208192A1 - CD200AR ligands for cancer immunotherapy - Google Patents

CD200AR ligands for cancer immunotherapy Download PDF

Info

Publication number
AU2020208192A1
AU2020208192A1 AU2020208192A AU2020208192A AU2020208192A1 AU 2020208192 A1 AU2020208192 A1 AU 2020208192A1 AU 2020208192 A AU2020208192 A AU 2020208192A AU 2020208192 A AU2020208192 A AU 2020208192A AU 2020208192 A1 AU2020208192 A1 AU 2020208192A1
Authority
AU
Australia
Prior art keywords
cd200ar
tumor
cells
cell
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020208192A
Other languages
English (en)
Inventor
Michael Olin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota System
Original Assignee
University of Minnesota Twin Cities
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota Twin Cities, University of Minnesota System filed Critical University of Minnesota Twin Cities
Publication of AU2020208192A1 publication Critical patent/AU2020208192A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2020208192A 2019-01-14 2020-01-13 CD200AR ligands for cancer immunotherapy Abandoned AU2020208192A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962792311P 2019-01-14 2019-01-14
US62/792,311 2019-01-14
PCT/US2020/013349 WO2020150149A1 (en) 2019-01-14 2020-01-13 Cd200ar ligands for cancer immunotherapy

Publications (1)

Publication Number Publication Date
AU2020208192A1 true AU2020208192A1 (en) 2021-08-05

Family

ID=69467802

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020208192A Abandoned AU2020208192A1 (en) 2019-01-14 2020-01-13 CD200AR ligands for cancer immunotherapy

Country Status (5)

Country Link
US (2) US12414983B2 (enExample)
EP (1) EP3911357B1 (enExample)
JP (1) JP7663237B2 (enExample)
AU (1) AU2020208192A1 (enExample)
WO (1) WO2020150149A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024259195A1 (en) * 2023-06-16 2024-12-19 Elias Animal Health Use of cd200ar-l for enhancing adoptive t-cell therapy
WO2025259866A2 (en) * 2024-06-14 2025-12-18 Elias Animal Health Combination of chemotherapy, cancer cell vaccine and adoptive cell therapy

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5744585A (en) 1995-03-16 1998-04-28 Medenica; Rajko D. Human monoclonal antibody against lung carcinoma
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US6955811B2 (en) 1997-11-07 2005-10-18 Trillium Therapeutics Inc. Methods of inhibiting immune response suppression by administering antibodies to OX-2
PT1032662E (pt) 1997-11-07 2006-07-31 Trillium Therapeutics Inc Metodos e composicoes para imunomodulacao.
AU2002223338B2 (en) 2000-11-22 2007-06-07 Trillium Therapeutics Inc. Truncated CD200
EP2463305B1 (en) 2006-01-12 2016-05-11 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof
JP2010534243A (ja) 2007-07-25 2010-11-04 アレクシオン ファーマシューティカルズ， インコーポレイテッド Ｃｄ２００に対する抗体および免疫応答への使用
US9555074B2 (en) 2010-10-08 2017-01-31 Regents Of The University Of Minnesota Annexin II compositions
FI123955B (en) 2011-11-25 2014-01-15 Oncos Therapeutics Ltd Oncolytic adenovirus
US9737598B2 (en) 2014-06-30 2017-08-22 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof
SG10201913573UA (en) * 2015-10-01 2020-03-30 Heat Biologics Inc Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
AU2016349897B2 (en) * 2015-11-03 2021-11-04 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof

Also Published As

Publication number Publication date
JP7663237B2 (ja) 2025-04-16
US20260158109A1 (en) 2026-06-11
JP2022517226A (ja) 2022-03-07
WO2020150149A1 (en) 2020-07-23
CA3126156A1 (en) 2020-07-23
EP3911357A1 (en) 2021-11-24
US20220088134A1 (en) 2022-03-24
US12414983B2 (en) 2025-09-16
EP3911357B1 (en) 2026-04-29

Similar Documents

Publication Publication Date Title
CN102858964B (zh) 多肽
CN101835892B (zh) Cdca1肽和包含cdca1肽的药剂
JP2018538265A (ja) 癌を治療するための方法及び組成物
EP2839291B1 (en) Multivalent breast cancer vaccine
EP3911357B1 (en) Cd200ar ligands for cancer immunotherapy
JP2020532553A (ja) 組み合わせがん療法
Puviindran et al. Within and beyond the tumor: Mechanisms of glioblastoma-induced immunosuppression
EP1706137A2 (en) M-csf muteins and uses thereof
EP4427761A1 (en) Vaccine against pancreatic cancer, and medical use thereof
US10576145B2 (en) CD200 inhibitors and methods of use thereof
CA3126156C (en) Cd200ar ligands for cancer immunotherapy
EP4065695A1 (en) Primary nk car constructs and methods
US20250302976A1 (en) New vaccinal strategy
JP6649953B2 (ja) 免疫療法による治療および組成物
EP4681724A1 (en) Protein for inhibiting excessive inflammatory response and use thereof
Zhang et al. Comparison of fusion protein and DC vaccine in inhibition of mouse B16F10 melanoma tumor
CN116139275A (zh) Cd300ld抑制剂在制备预防、诊断或治疗肿瘤产品中的用途
US20240317833A1 (en) Non-hla restricted t cell vaccine for tcr gamma alternate reading frame protein (tarp) protein expressing cancers
WO2024097096A1 (en) Methods for treating and preventing b cell disorders
CN121824722A (zh) 一种肿瘤免疫治疗多肽及其应用
JP6356317B1 (ja) 多発性骨髄腫患者の医薬への応答性を判定する方法、並びに多発性骨髄腫患者における骨病変の予防及び／又は治療のための医薬
HK40114150A (en) Immunostimulatory mrna compositions and uses thereof
TW202241488A (zh) 治療癌症之方法
WO2003090675A2 (en) Methods and compositions useful for treating prostate cancer
EP3615063A1 (en) Mesothelin vaccine for ovarian cancer prevention

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application